A Phase 2 Study of Temozolomide Plus Vorinostat in Patients With Relapse/Refractory Acute Myeloid Leukemia (AML)

Trial Profile

A Phase 2 Study of Temozolomide Plus Vorinostat in Patients With Relapse/Refractory Acute Myeloid Leukemia (AML)

Suspended
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Vorinostat (Primary) ; Temozolomide
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jul 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2019.
    • 31 Jul 2017 Planned primary completion date changed from 30 Jun 2017 to 31 Mar 2019.
    • 31 Jul 2017 Status changed from active, no longer recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top